Curaxin CBL0137 inhibits endothelial inflammation and atherogenesis via suppression of Src-YAP signaling axis.

To our knowledge, this is the first study that identifies CBL0137 as a novel YAP inhibitor and we demonstrate that pharmacologically targeting YAP by CBL0137 inhibits atherogenesis. The present results suggest that CBL0137 holds promise as a new drug for the treatment of atherosclerotic vascular disease.